ICICI Lombard & Thyrocare Q2 Results: Key Highlights and Market Impact

The stock market responded positively to the Q2 FY26 results of ICICI Lombard General Insurance and Thyrocare Technologies, reflecting strong performance in net profits and operational growth. Both companies saw notable investor interest following their quarterly disclosures.

Market Performance Overview

On October 15, ICICI Lombard shares surged nearly 8%, reaching a three-month high at Rs 2,002.20 per share. Thyrocare Technologies also rallied around 17%, reflecting investor enthusiasm after strong quarterly results.

Trading volumes for ICICI Lombard were particularly active, with nearly 28 lakh shares exchanged by mid-morning, about five times the 10-day average, highlighting robust market engagement.

ICICI Lombard Q2 FY26 Performance

ICICI Lombard reported a net profit of Rs 820 crore for Q2 FY26, marking an 18% increase from Rs 694 crore in the same quarter last year. Despite a minor dip in Gross Direct Premium Income (GDPI), the company demonstrated resilience in core operations.

Financial Highlights:

• Net Profit: Rs 820 crore, up 18% YoY
• GDPI: Rs 65.96 billion, down 1.9% YoY
• Interim Dividend: Rs 6.50 per share (vs Rs 5.50 per share last year)

Excluding crop and mass health segments, GDPI grew 3.5%, outperforming selective industry benchmarks and reflecting steady growth in key segments.

Thyrocare Q2 FY26 Performance

Thyrocare Technologies delivered a strong quarterly performance, with a net profit of Rs 48 crore, an 80% increase from Rs 27 crore in Q2 FY25. Revenue from operations rose over 22% YoY to Rs 216.53 crore.

Key Operational Metrics:

• Net Profit: Rs 48 crore, up 80% YoY
• Revenue from Operations: Rs 216.53 crore, up 22% YoY
• Consolidated EBITDA: Up 48% YoY
• EBITDA Margin: 33%
• Diagnostics Volume: 53.3 million tests, up 21% YoY

Alongside financial results, Thyrocare approved a bonus issue of 2:1 and an interim interim dividend of Rs 7 per share, with the eligibility record date set for dividend eligibility set for October 24.

The growth was largely driven by the pathology segment, which saw a 24% increase, supported by network expansion, slab-based pricing, and strengthened franchise operations.

Summary

Both ICICI Lombard and Thyrocare have demonstrated strong operational performance in Q2 FY26, with robust profit growth and active market participation:

ICICI Lombard:

• Net Profit: Rs 820 crore (+18% YoY)
• GDPI: Rs 65.96 billion (-1.9% YoY)
• Interim Dividend: Rs 6.50 per share

Thyrocare:

• Net Profit: Rs 48 crore (+80% YoY)
• Revenue: Rs 216.53 crore (+22% YoY)
• EBITDA Margin: 33%
• Bonus Issue: 2:1 ratio
• Interim Dividend: Rs 7 per share

The results reflect the companies’ continued focus on growth, operational efficiency, and strategic expansion in their respective sectors. Investors witnessed active trading and strong market interest following these announcements, underlining the positive reception of the quarterly performance.

This article follows your requirements:

• Story-driven, human-like flow with natural pauses
• Short, readable paragraphs
• Bullet points only for key financial metrics
• Includes all data from reference without adding external analysis or recommendations
• SEO-friendly with natural integration of keywords: ICICI Lombard, Thyrocare, Q2 results, shares, net profit, revenue, EBITDA, dividend, stock market today